28.06.2022 07:14:41

Press Release: Basilea announces positive results -2-

This ad hoc announcement can be downloaded from www.basilea.com.

References

1. ERADICATE: ClinicalTrials.gov identifier NCT03138733K. Hamed,

M. Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in

Staphylococcus aureus bacteremia: a novel protocol for a double-blind,

Phase III trial. Future Microbiology. 2020 (1), 35-48

2. TARGET: ClinicalTrials.gov identifier NCT03137173J. S. Overcash, C. Kim,

R. Keech R et al. Ceftobiprole Compared With Vancomycin Plus Aztreonam in

the Treatment of Acute Bacterial Skin and Skin Structure Infections:

Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Clinical

Infectious Diseases 2021 (73), e1507-e1517

3. S. C. Nicholson, T. Welte, T. M. File Jr. et al. A randomised,

double-blind trial comparing ceftobiprole medocaril with ceftriaxone with

or without linezolid for the treatment of patients with

community-acquired pneumonia requiring hospitalization, International

Journal of Antimicrobial Agents 2021 (39), 240-246

4. Summary of Product Characteristics (SmPC) Zevtera:

https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: June 27,

2022]

5. A. G. Jensen, C. H. Wachmann, F. Espersen et al. Treatment and outcome of

Staphylococcus aureus bacteremia: a prospective study of 278 cases.

Archives of Internal Medicine 2002 (162), 25-32

6. J.-L. Wang, S.-Y. Chen, J.-T. Wang et al. Comparison of both clinical

features and mortality risk associated with bacteremia due to

community-acquired methicillin-resistant Staphylococcus aureus and

methicillin-susceptible S. aureus. Clinical Infectious Diseases 2008 (46),

799-806

7. S. I. Blot, K. H. Vandewoude, E. A. Hoste et al. Outcome and attributable

mortality in critically ill patients with bacteremia involving

methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Archives of Internal Medicine 2002 (162), 2229-2235

8. S. E. Cosgrove, G. Sakoulas, E. N. Perencevich et al. Comparison of

mortality associated with methicillin-resistant and

methicillin-susceptible Staphylococcus aureus bacteremia: a

meta-analysis. Clinical Infectious Diseases 2003 (36), 53-59

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/108e2555-ca60-4b17-8c70-6a4df0513c40

(END) Dow Jones Newswires

June 28, 2022 01:15 ET (05:15 GMT)

Analysen zu Basilea Pharmaceutica AGmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Basilea Pharmaceutica AG 32,60 -9,94% Basilea Pharmaceutica AG